Loading
Anti-PD-1 and PD-L1 agent / TT-702 / Advanced Solid Tumors · Phase 1/2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1/2 trial of TT-702, a novel investigational agent, in patients with advanced solid tumours. The study aims to establish maximum tolerated dose as monotherapy and in combination with anti-PD-1/PD-L1 agents. No results are currently available in this registry record.
Phase 1/2, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Advanced Solid Tumors; age from 16 Years. Intervention: Cohort 1M (Monotherapy escalation cohort); Cohort 2M: (Monotherapy expansion cohort); Cohort 1P (Combination escalation cohort); Cohort 2P (Combination expansion cohort). n = 60. 3 sites: United Kingdom.
This is a planned Phase 1/2 trial of TT-702, a novel investigational agent, in patients with advanced solid tumours. The study aims to establish maximum tolerated dose as monotherapy and in combination with anti-PD-1/PD-L1 agents. No results are currently available in this registry record.
Primary outcomes focus on safety and early efficacy signals; mature efficacy and long-term safety data are not yet available.
This trial is in early recruitment and no efficacy or safety data are yet available. Clinicians should await completion and publication of results before considering clinical application.
This is a Phase 1/2 trial registry record with no results reported; it describes a planned study of an investigational agent in early development stages.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment and no efficacy or safety data are yet available. Clinicians should await completion and publication of results before considering clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05272709). This is a study registration, not published results. Lead sponsor: Cancer Research UK. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Advanced Solid Tumors. Interventions: DRUG: TT-702; DRUG: Anti-PD-1 and PD-L1 agent. Primary outcome measures: Number of Dose Limiting Toxicities (DLTs) (Dose Escalation Phase) , From the first dose in Cycle 0, until completion of Cycle 1 (3 weeks [+ 3-9 days to account for initial pharmacokinetic (PK) profiling period following the Cycle 0 dose]).; Number of Treatment-Emergent AEs (TEAEs), Related TEAEs and Grade 3, 4 or 5 TEAEs (Dose Escalation Phase) , From the time of first dose until the end of the safety follow-up period for TT-702.; Objective Response Rate (ORR) , From the first dose and until the final radiological disease assessment at the off-study visit.; Number and Percentage of Participants that Achieved Clinical Benefit Assessed by PCWG3 and RECIST v1.1 (Expansion Phase) , From the first dose and until the final radiological disease assessment at the off-study visit.. Brief summary: This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.